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Abstract
Background: Dissociating glucocorticoid receptor (GR) ligands hold great promise for treating inflammatory disorders since
it is assumed that they exert beneficial activities mediated by transrepression but avoid adverse effects of GR action
requiring transactivation. Here we challenged this paradigm by investigating 2-(4-acetoxyphenyl)-2-chloro-N-methyl-
ethylammonium chloride (CpdA), a dissociating non-steroidal GR ligand, in the context of experimental autoimmune
encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
Methodology/Principal Findings: CpdA inhibited pro-inflammatory mediators in myelin-specific T cells and fibroblasts in a
GR-dependent manner while gene activation was abolished. However, it also induced massive apoptosis in various cell
types even in the absence of the GR by engaging a Bcl-2- and caspase-dependent pathway.
1H NMR spectroscopy
corroborated these findings by revealing that CpdA dissolved in buffered solutions rapidly decomposes into aziridine
intermediates known to act as alkylating pro-apoptotic agents. Importantly, the dichotomy of CpdA action also became
evident in vivo. Administration of high-dose CpdA to mice was lethal while treatment of EAE with low to intermediate
amounts of CpdA dissolved in water significantly ameliorated the disease. The beneficial effect of CpdA required expression
of the GR in T cells and was achieved by down regulating LFA-1 and CD44 on peripheral Th cells and by repressing IL-17
production.
Conclusions/Significance: CpdA has significant therapeutic potential although adverse effects severely compromise its
application in vivo. Hence, non-steroidal GR ligands require careful analysis prior to their translation into new therapeutic
concepts.
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Introduction
Glucocorticoids (GCs) are amongst the most potent anti-
inflammatory drugs presently available and are widely used to
treat chronic inflammatory diseases such as rheumatoid arthritis
(RA) and multiple sclerosis (MS) [1–3]. Nevertheless, GC therapy
is often complicated by severe adverse effects such as osteoporosis,
muscle atrophy or diabetes [4,5]. Therefore, it remains a challenge
to develop new GC analogues with similar efficacy but reduced
side effects.
Since their first clinical use more than half a century ago [6],
GCs have been modified in multiple ways to improve their
pharmacological characteristics. One strategy is based on the
notion that adverse effects are often mediated by transactivation
after GR binding to promoter and enhancer elements present in
target genes. In contrast, transrepression was hypothesized to
underlie many beneficial effects that proceed without DNA-
binding and rather depend on the interference of the monomeric
GR with transcription factors such as NF-kB or AP-1 [7]. Support
for this concept came from of the analysis of GR
dim mice that are
defective in GR dimerization and DNA-binding [8,9]. Important-
ly, several cytokines in these mice are fully repressed by GC
treatment while regulation of many genes involved in metabolic
side effects is abolished [8,9]. This model stimulated the search for
new dissociating GR ligands that predominantly act via transre-
pression such as ZK 216348 [10], AL-438 [11] or 2-(4-
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known as Compound A (CpdA) [12].
CpdA is a synthetic analogue of a substance that naturally
occurs in the Namibian shrub Salsola tuberculatiformis Botschantzev.
It has contraceptive activity [12], exerts anti-androgenic effects
[13] and binds to serum proteins such as corticosteroid-binding
globulin (CBG) and albumin [14]. Biochemical analysis revealed
that CpdA and the classical GC dexamethasone (Dex) both
interact with the GR at high affinity [15]. Additionally, it could be
shown that CpdA at a dose of 10
25 M down regulates NF-kB
driven gene expression without inducing GC response element
(GRE) dependent genes [15]. These results are compatible with
the concept that CpdA represents a dissociating GR ligand.
Analysis of two mouse models further supported the idea that
CpdA has potent anti-inflammatory activity but exerts only little
side effects when applied in vivo. Preventive administration in the
acute zymosan-induced paw inflammation model in C57Bl/6
mice and therapeutic treatment of collagen type II induced RA in
DBA/1 mice both efficiently interfered with disease progression in
the absence of metabolic side effects [15,16]. Therefore, CpdA was
considered a promising candidate for possible future application in
humans. Nevertheless, a detailed dose response analysis of CpdA
in vivo has not been reported to date.
MS is an inflammatory demyelinating autoimmune disease of
the central nervous system (CNS), which is associated with severe
functional deficits. Many of its hallmarks can be studied in
experimental autoimmune encephalomyelitis (EAE), a frequently
used animal model for MS [17]. Initially, autoreactive T cells cross
the blood-brain barrier and initiate an inflammatory response
succeeded by the influx of additional leukocytes and an
amplification of the immune response. High-dose GC therapy
confers significant therapeutic benefit to MS patients suffering
from acute relapses [3,18], which is similarly observed after
treatment of EAE. Experiments in mice revealed that T cells but
not macrophages are the essential targets of GC therapy [19].
Although lymphocyte infiltration into the CNS was diminished
after GC treatment, T cell apoptosis and expression of adhesion
molecules in the spinal cord remained unaltered. In contrast,
splenic T cells showed significantly increased apoptosis, reduced
surface levels of LFA-1, CD44 and VLA-4 and impaired
lymphocyte migration to the inflamed CNS [19]. Hence, GC
therapy of EAE impacts T cells via the transactivating as well as
the transrepressing function of the GR.
In this study, we addressed the question whether CpdA was
suitable for the treatment of EAE. Although we could confirm the
dissociating character of CpdA in vitro and in vivo, it additionally
induced apoptosis independent of the GR in a variety of cell types
including lymphocytes, neuronal cells and fibroblasts.
1H nuclear
magnetic resonance (NMR) spectroscopy revealed that CpdA
rapidly decomposes into aziridine derivatives when dissolved in
buffered solutions while it is rather stable in pure water. Based on
these findings we identified conditions that allowed successful
treatment of EAE induced in C57Bl/6 mice. However, when
CpdA was administered at high concentration it turned out to be
lethal. We conclude that a detailed characterization of dissociating
GR ligands is mandatory to adequately judge their suitability for
future therapeutic application.
Methods
Mice
C57Bl/6 wildtype mice were purchased from Harlan Winkel-
mann (Borchen, Germany); GRN and GR
lckCre mice were
previously described [20,21]. All animal experiments were
conducted according to ethical standards of humane animal care
and approved by the authorities of Lower Saxonia (LAVES).
Reagents
2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chlo-
ride (Compound A) was purchased from Merck Biosciences
(Schwalbach, Germany) and stored at 280uC until use. Water-
soluble dexamethasone (Dex) for cell-culture was from Sigma
(Taufkirchen, Germany), dexamethasone-21-dihydrogen-phos-
phate for EAE therapy from Ratiopharm (Ulm, Germany) and
Z-VAD-fmk from R&D Systems (Wiesbaden, Germany).
Flow Cytometry
All antibodies and reagents were obtained from BD Biosciences
(Heidelberg, Germany): anti-CD3e (145-2C11), anti-CD4 (RM4-
5), anti-CD44 (IM7), anti-CD11a/LFA-1 (2D7), anti-IFNc (DB-1)
and anti-IL-17 (TCII-18H10), 7-AAD and AnnexinV. The
antibodies and AnnexinV were directly labeled with FITC, PE,
PerCP, PE-Cy7, Cy5, APC or APC-Cy7. Extracellular and
intracellular stainings were performed as previously described
[19] and analyzed using a FACS Canto II device allowing for the
detection of six fluorescent dyes (BD Biosciences).
In Vitro Cell Culture Experiments
Clonal lines of encephalitogenic T (Tenc) cells specific for guinea
pig myelin basic protein (gpMBP) were established by immuniza-
tion of Lewis rats followed by antigen restimulation in vitro as
described [22]. Tenc cells and thymocytes were cultured in RPMI
1640 medium (Invitrogen, Karlsruhe, Germany) with Glutamax,
10% FCS and 1% standard antibiotics. Mouse embryonic
fibroblasts (MEFs), WEHI 7.1 mouse thymoma and SK-N-SH
neuroblastoma cells were cultured in DMEM medium (Invitrogen)
with Glutamax, 10% FCS and 1% standard antibiotics.
For functional analyses, Tenc cells were cultured in the presence
of 10 mg/ml gpMBP and irradiated T cell-depleted rat splenocytes
at a 1:1 ratio (1610
6 cells in total in a 24-well plate) for 12 hrs,
followed by additional 5 hrs in the presence of the respective
hormones. To determine cytokine production, the cells were
treated with Golgi-Plug (BD Biosciences) during the last 2 hrs
according to the manufacturer’s instructions. To induce MMP-13
expression MEFs were treated for 5 hrs with 5 ng/ml PMA.
Quantitative Polymerase Chain Reaction (PCR)
Total RNA was isolated using TriZol reagent according to
standard procedures (Invitrogen) followed by DNaseI treatment
and purification with the RNeasy Mini Kit (Qiagen, Hilden,
Germany). 1 mg of RNA were reversely transcribed into cDNA
using the BioRad iScript kit (Munich, Germany). Real-time PCR
was performed on an ABI 7500 instrument (Applied Biosystems,
Darmstadt, Germany) using the SYBR mastermix from the same
company according to the manufacturer’s instruction. The results
were normalized to b-actin expression and evaluated using the
relative quantification method.
Generation of Retrovirally Transduced Cells
The vector pEYZ/MCS-bcl-2 is described elsewhere [23]. An
shRNA specific for the mouse GR (TGCTGTTGACAGT-
GAGCGCG GCGATACCAGGATTCAGAAATA GTGAAG-
CCACAG ATG TATTTCTGAATCCTGGTATCGC CTTG-
CCTACTGCCTCGGA) was cloned into the retroviral vector
MSCV-LMP (Open Biosystems, Huntsville, AL, USA) to obtain
LMP-msiGR. Viral particles were generated following published
protocols [23] and directly used to transduce WEHI 7.1 cells by
GR Ligand in a Model of MS
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culture in the presence of 2 mg/ml puromycin (LMP-msiGR) or
200 mg/ml neomycin (pEYZ/MCS-bcl-2). Purity was assessed by
flow cytometry on the basis of eGFP expression and found to be
greater than 99%.
1H Nuclear Magnetic Resonance (NMR) Spectroscopy
Decay of CpdA was monitored by
1H NMR spectroscopy at a
concentration of 5 mM in 100 mM phosphate buffer with pH
values of 8.1, 7.7, 7.1 and 6.7. The buffer solutions were prepared
by dissolving mixtures of KH2PO4 and K2HPO4 in D2O followed
by pH measurement using a glass electrode [24]. In addition,
decay of CpdA was analyzed in pure D2O (pH 7.0), PBS
(100 mM, pH 7.6) or Tris-HCl buffer (100 mM, pH 7.6). The
dissolved CpdA was quickly transferred into the magnet of a
Bruker Avance 500 MHz NMR spectrometer (Rheinstetten,
Germany) using a 5 mm NMR tube followed by recording of
1H NMR spectra (20 scans, 2.75 s acquisition) at 25uC in intervals
of 1 min for up to 3 hrs. Hydrolysis to acetyl synephrine and
synephrine was monitored over a period of 21 days. Aromatic
resonances were used for integration, and the peak integrals of
CpdA were fitted to a monoexponential decay using Origin
(OriginLab, Northampton, MA, USA). Peak assignments for
CpdA, the two isomeric aziridines and acetyl synephrine were
established by COSY (8 scans, 51261024 data points, 2 h) and
NOESY (8 scans, 0.5 s mixing, 2.5 h) experiments. Chemical shifts
[25] and coupling constants [26] were in agreement with previous
reports.
EAE Induction and Treatment Protocols
C57Bl/6 mice or GR
lckCre mice on the same genetic
background were immunized with 50 mg MOG35–55 peptide in
CFA as previously described [19]. Animals were weighed and
scored daily for clinical signs of the disease on a scale from 0 to 10
depending on its severity; scores were as followed: 0=normal;
1=reduced tone of tail; 2=limp tail, impaired righting; 3=absent
righting; 4=gait ataxia; 5=mild paraparesis of hindlimbs;
6=moderate paraparesis; 7=severe paraparesis or paraplegia;
8=tetraparesis; 9=moribund; 10=death.
To analyze the effects of CpdA therapy, the drug was dissolved
in 150 ml ethanol (20% vol/vol), pure water or PBS and injected
i.p. on 3 consecutive days. For comparative analysis we injected
Dex dissolved in PBS following the same time schedule.
Proliferation Assay and ELISA
Single cell suspensions were prepared from spleen of C57Bl/6
mice immunized with MOG35–55 on the day after the third
treatment with CpdA or PBS as a control. 3610
5 cells were seeded
in 96 well microtiter plates (Nunc, Wiesbaden, Germany) in 100 ml
medium each in the presence or absence of MOG35–55 peptide
(20 mg/ml) or ConA (1.25 mg/ml). Triplicate cultures were
maintained at 37uC in a humidified incubator with 5% CO2 for
56 hrs and harvested following a 16 hrs pulse with 0.2 mCi/well
3[H]-thymidine (Perkin Elmer, Rodgau, Germany). Cells were
collected on fiberglass filter paper and the incorporated radioac-
tivity was measured using a b-plate liquid scintillation counter
(Perkin Elmer). To determine cytokine secretion, 5610
6 cells were
seeded in 24 well microtiter plates in the presence or absence of
MOG35–55 peptide or ConA as described above. The supernatants
were collected 72 hrs later and the cytokine levels were
determined by commercially available ELISA kits for IFNc (BD
Bioscience) and IL-17 (R&D Systems, Wiesbaden, Germany)
according to the manufacturers’ instructions. All experiments were
at least performed twice.
Statistical Analysis
Analysis was performed by Mann-Whitney or Students t-test
and the data depicted as mean 6 SEM; *: p,0.05, **: p,0.01,
***: p,0.001, n.s.: p.0.05. To determine differences referring to
the EAE disease course, the whole curves were compared between
experimental groups starting on the day after the first treatment
until the end of the observation period.
Results
CpdA Allows Dissociating GR-Mediated Transrepression
from Transactivation in Myelin-Specific T Effector Cells
and Mouse Embryonic Fibroblasts
CpdA had been reported to possess properties reminiscent of
bona fide dissociating GCs. To confirm this characteristic with
regard to the suitability of CpdA for the treatment of EAE and
possibly MS, we tested its transrepression and transactivation
activity in encephalitogenic T cells (Tenc). These myelin-specific T
effector cells are able to induce an MS-like pathology after
adoptive transfer into rodents and resemble the pathogenic T
lymphocytes found in MS patients. Initially, we analyzed
production of IFNc and IL-17, two cytokines that are involved
in the pathogenesis of MS [27]. Treatment of Tenc cells with
10
26 M Dex as well as 10
25 M CpdA for 5 hrs diminished
production of both pro-inflammatory mediators by around 60%
based on intracellular flow cytometric analysis (Fig. 1A). In
contrast, addition of 10
25 M CpdA did not alter the expression of
the bona fide GR target gene glucocorticoid-induced leucin zipper
(GILZ) in Tenc cells while treatment with 10
26 M Dex strongly
increased it (Fig. 1B). CpdA at a concentration of 10
26 M neither
altered cytokine production nor GILZ expression (data not
shown). Importantly, no apoptosis was detected within the 5 hrs
culture period, thus excluding that the observed effects were linked
to cell death (data not shown). We conclude that CpdA acts in a
truly dissociating manner in myelin-specific T cells.
To examine whether CpdA exerts its repressive activity via the
GR, we studied regulation of matrix metalloproteinase 13 (MMP-
13) in mouse embryonic fibroblasts (MEFs). MMP-13 expression is
controlled by the transcription factor AP-1 and becomes repressed
by GCs through direct protein-protein-interaction of the GR with
AP-1 [28]. Wildtype (GRN
+/+) and GR-deficient (GRN
2/2)
MEFs were stimulated with PMA in the presence of 10
26 M Dex
or 10
25 M CpdA followed by quantitative RT-PCR analysis.
MMP-13 expression in wildtype cells was efficiently reduced by
either treatment, while the inhibitory effect of both substances was
fully abolished in MEFs from GRN
2/2 mice (Fig. 1C). CpdA at a
concentration of 10
26 M had no effect on MMP-13 expression
(data not shown). Taken together, CpdA allows dissociating
transactivation from GR-mediated transrepression.
CpdA Induces Apoptosis in Various Cell Types
GCs are potent inducers of lymphocyte apoptosis, which
significantly contributes to their anti-inflammatory and immuno-
suppressive activity. In contrast, many other cell types such as
neurons and fibroblasts are resistant to GC-induced cell death. To
determine whether CpdA shares these features with traditional
GCs, we initially cultured immature thymocytes, which are known
to be particularly sensitive to GC-mediated apoptosis, in the
presence of 10
26 M Dex or 10
25 M CpdA for 24 hrs. Flow
cytometric analysis performed at various time intervals revealed
that both substances efficiently induced thymocyte apoptosis,
although with different kinetics (Fig. 2A). Eventually most cells
died irrespective of the treatment, which could be prevented by
incubation with the pan-caspase inhibitor Z-VAD-fmk (Fig. 2B).
GR Ligand in a Model of MS
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hematopoietic cell types, we cultured SK-N-SH cells, a human
neuroblastoma cell line, in the presence of 10
26 M Dex or
10
25 M CpdA for 24 hrs. While Dex didn’t compromise the
viability of these cells, incubation with CpdA strongly induced
apoptosis. Again, this could be prevented by co-incubation with
the pan-caspase inhibitor Z-VAD-fmk, confirming that cell death
was not the result of unspecific necrosis (Fig. 2C). Thus, CpdA
induces apoptosis in neuronal cells that are normally resistant to
GC treatment.
In view of the unusually high apoptotic potency of CpdA we
tested its effect on fibroblast growth. As expected, treatment of
mouse embryonic fibroblasts (MEFs) for 48 hrs with 10
26 M Dex
had no effect whilst CpdA significantly diminished cell numbers
when added at a concentration of 10
25 M (Fig. 2D). This effect
was mediated - at least in part - by induction of apoptosis (data not
shown). Surprisingly, we obtained similar results in MEFs derived
from GRN
+/+ and GRN
2/2 mice, indicating that the GR was not
essential for the observed effects. This suggests that CpdA also
engages GR-independent signaling pathways.
CpdA Induces Apoptosis through the Mitochondrial
Pathway in a GR-Independent Manner
Alerted by the striking findings in MEFs we performed
additional studies on the role of the GR in CpdA-induced
apoptosis. Since GR-deficient mice are not viable, we analyzed
thymocytes from GRN
+/+ or GRN
2/2 embryos at day E18.5.
Incubation of wildtype cells with increasing amounts of Dex for
24 hrs resulted in the induction of cell death following a sigmoid
curve [21]. In contrast, GR-deficient thymocytes were completely
resistant at all Dex concentrations tested (Fig. 3A). When we
treated thymocytes for 24 hrs with CpdA, cell survival sharply
declined from nearly unimpaired viability at 10
26 M to almost
complete cell death at 10
25 M (Fig. 3B). Most importantly,
thymocytes from GRN
2/2 embryos were as sensitive to CpdA-
induced apoptosis as wildtype cells (Figure 3B). Similar results
were obtained with adult T cell-specific GR knockout mice (data
not shown). Collectively, CpdA efficiently induces thymocyte
apoptosis in a GR-independent manner.
To obtain further insight into the molecular mechanism of
CpdA, we analyzed WEHI 7.1 cells, a Dex-sensitive mouse
thymoma cell line (Fig. 3C). Initially, we silenced the GR by
retroviral delivery of a specific microRNA followed by incubation
of the stably transduced cells with different concentrations of Dex
or CpdA for 48 hrs. Flow cytometric analysis confirmed our
earlier findings in thymocytes showing that GR inactivation
compromised Dex-induced cell death in WEHI 7.1 cells while the
pro-apoptotic activity of CpdA was unaffected (Fig. 3C,D). To
explore whether the mitochondrial pathway was responsible for
CpdA induced apoptosis, we expressed Bcl-2 in WEHI 7.1 cells by
retroviral transduction. Interestingly, Bcl-2 overexpression com-
pletely prevented cell death caused by both drugs (Fig. 3C,D). This
confirms that CpdA induces apoptosis rather than exerting
unspecific toxic effects.
CpdA Decays into Aziridine Derivatives and Synephrine
in a Solvent-Dependent Manner
CpdA dissolved in phosphate-buffered solution was previously
shown to decompose into the corresponding aziridine, which is
inhibited by serum proteins [12]. Interestingly, such compounds
encompass several highly reactive alkylating cytostatic drugs used
in cancer therapy. Thiotepa for example induces apoptosis in
breast cancer and leukemia cell lines through activation of the
Figure 1. CpdA mediates transrepression in myelin-specific T
effector cells via the GR but not transactivation. (A) Tenc cells
were cultured in the presence of APCs and 10 mg/ml gpMBP, either
treated with 10
26 M Dex or 10
25 M CpdA for 6 hrs or left untreated
(con). IFNc and IL-17 production was assessed by intracellular flow
cytometry and normalized to each control (100%) based on the
percentage of cells positively staining for the respective cytokines. n=3.
(B) Tenc cells were cultured in the presence of 10
26 M Dex or 10
25 M
CpdA for 6 hrs followed by the analysis of GILZ mRNA expression by
quantitative RT-PCR. The expression levels were normalized to the
housekeeping gene b-actin and the results are depicted as fold
induction relative to untreated control cells. n=3. (C) MEFs derived
from GRN
+/+ mice (wildtype cells) and GRN
2/2 mice (GR-deficient cells)
were preincubated with 5 ng/ml PMA for 1 hr. Subsequently, they were
stimulated with 10
26 M Dex or 10
25 M CpdA for 5 hrs or left untreated
(con). MMP-13 mRNA expression was determined by quantitative
RT-PCR and normalized to b-actin. MMP-13 levels in the medium
controls were set as 100%. n=3. *: p,0.05, **: p,0.01, ***: p,0.001,
n.s.: p.0.05.
doi:10.1371/journal.pone.0008202.g001
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be prevented by pan-caspase inhibitors [29,30]. Since CpdA exerts
similar pro-apoptotic effects in a GR-independent manner, we
wanted to reevaluate the conditions under which CpdA decom-
poses as a basis for a possible correlation between chemical decay
and biological activity in vitro and in vivo.
To investigate the stability and conversion of CpdA under
different physico-chemical conditions we used
1H NMR spectros-
copy. When dissolved in pure water (pH=7.0) CpdA slowly
underwent hydrolysis to acetyl synephrine without formation of
cyclic intermediates (half life: 5.560.3 days). Within a few weeks
further hydrolysis to synephrine, an a-adrenergic receptor agonist
was observed (Fig. 4A). When we dissolved CpdA in PBS
(pH=7.6) or Tris-HCl buffer (pH=7.6) rapid formation of two
reaction intermediates occurred, which we could identify as the
isomeric forms of N-methyl-2-(4-acetoxyphenyl)-aziridine (Fig. 4A).
Both isomers are typically formed within a few minutes, with rates
2–3 times higher in Tris-HCl as compared to PBS. Subsequently
both aziridines are hydrolyzed to acetyl synephrine within a few
days. Interestingly, the rate of aziridine formation is strongly pH-
dependent with the half-life of CpdA varying from a few minutes
at pH=8.1 to about 2 hrs at pH=6.7 (Figure 4B). A logarithmic
plot of the half-life of CpdA versus the respective pH value showed
a linear dependency with high correlation (Fig. 4B). The data are
thus in agreement with the notion that cyclization - involving
nucleophilic attack of the nitrogen atom under elimination of
chloride - requires the amino form of CpdA, while the protonated
ammonium is not reactive.
We conclude that the predominant chemical form of CpdA
present in solution depends on the pH and buffer conditions. The
aziridine derivatives that presumably account for the GR-
independent pro-apoptotic activity are mainly formed in buffered
solutions while CpdA is relatively stable when dissolved in water.
Thus, the different cellular effects of CpdA could be linked to the
formation of decay products.
CpdA Exerts Dose-Dependent Therapeutic and Adverse
Effects in a Mouse Model of MS
EAE is a widely used animal model of MS and represents one of
the best-studied examples for therapeutic intervention by GCs.
Since we had previously found that administration of Dex
ameliorates MOG35–55 induced EAE in C57Bl/6 mice [19] and
since CpdA was shown to repress inflammatory arthritis in two
mouse models [15,16], we wondered whether CpdA was also able
to interfere with EAE in mice. Moreover, we were curious whether
the previously observed GR-independent pro-apoptotic activity of
CpdA also plays a role in vivo and how this may impact the
suitability of CpdA as a therapeutic agent. Following published
protocols we intraperitonally administered 15 mg/kg CpdA [16]
or 100 mg/kg Dex [19] on 3 consecutive days to C57Bl/6 mice
after manifestation of first EAE symptoms. In agreement with
previous findings, Dex significantly ameliorated EAE [19]. In
contrast, CpdA severely aggravated the disease course rather than
having a beneficial effect. Strictly speaking, all animals died within
72 hrs after CpdA administration or had to be sacrificed for
Figure 2. CpdA exerts pro-apoptotic activity in various cell-types. (A) Thymocytes were cultured in the presence or absence of 10
26 M Dex
or 10
25 M CpdA for 24 hrs. Apoptosis was assessed at different time points by flow cytometry based on staining for AnnexinV/7-AAD. Survival of
untreated cells was set as 100% for each time point to correct for spontaneous apoptosis. n=3. (B) Thymocytes were treated with Dex or CpdA for
24 hrs as in panel A, either in the absence (con) or the presence of 100 mM Z-VAD-fmk (pan-caspase inhibitor). n=3. (C) SK-N-SH neuroblastoma cells
were treated with Dex or CpdA at concentrations of 10
26 M and 10
25 M for 24 hrs or left untreated (con). To test whether CpdA action depends on
caspase-activity, the experiment was additionally performed in the presence of 100 mM Z-VAD-fmk. n=6. (D) 5610
4 MEFs generated from GRN
+/+ and
GRN
2/2 fetuses were cultured in the absence (con) or presence of 10
26 M Dex or 10
25 M CpdA. After 48 hrs cell numbers were determined by
microscopic counting. n=3. *: p,0.05, **: p,0.01, ***: p,0.001, n.s.: p.0.05.
doi:10.1371/journal.pone.0008202.g002
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non-immunized mice was also lethal (data not shown), confirming
that high-dose CpdA was intrinsically toxic. In particular, the
clinical symptoms that precede death after CpdA application
include abdominal pain, ataxia and intestinal necrosis at the site of
injection (data not shown).
Next, we tested the therapeutic efficacy and potential side effects
of CpdA at lower concentrations. In contrast to high-dose CpdA,
application of 5 mg/kg as well as 1.5 mg/kg CpdA dissolved in
water significantly ameliorated the disease (Fig. 5B). The beneficial
effect was slightly more pronounced at the intermediate as
compared to the low dose and, irrespective of its concentration,
CpdA was somewhat less potent than Dex (Fig. 5A,B). Impor-
tantly, however, we didn’t notice any obvious adverse effects under
these conditions. Taken together, these findings suggest that
treatment of EAE by CpdA is possible although only in a narrow
therapeutic window. Notably, when we dissolved CpdA in PBS
instead of water thereby decreasing its chemical stability (see
above), the beneficial effect was partially lost (data not shown).
This strongly indicates that therapeutic activity can be assigned to
CpdA itself rather than the aziridine intermediate.
Finally, we determined whether the GR in T cells was essential for
therapeutic efficacy of CpdA in EAE. To this end, we used
conditional GR knockout mice (GR
lckCre), which specifically lack
the GR in T cells [19]. While EAE in GR
flox control mice could be
significantly treated by 5 mg/kg CpdA, the disease course was not
affected in GR
lckCre mice(Fig.5C).Thisconfirmsthatthetherapeutic
effect of CpdA is mediated via the GR by modulating T cell function.
In view of our previous finding that CpdA induces apoptosis in
vitro at high concentrations independent of the GR (see above), we
wondered whether there was a link between this feature and the
side effects that CpdA exerts in vivo. To address this question we
injected C57Bl/6 mice either with the high (15 mg/kg) or the
intermediate (5 mg/kg) dose of CpdA on 3 consecutive days
followed by enumerating splenocyte numbers. Treatment with the
intermediate dose mildly diminished the cellularity of the spleen
but without reaching significance (Fig. 5D). This effect was
independent of the GR since CpdA exerted a similar effect in
GR
lckCre mice, which are refractory to apoptosis induction by GR
ligands (Fig. 5D). Remarkably, however, administration of high-
dose CpdA to C57Bl/6 mice led to a strong and significant
reduction in splenocyte numbers by almost 80% (Fig. 5D). We
conclude that CpdA at high concentration causes massive
lymphocyte death, which correlates with the manifestation of side
effects.
CpdA Ameliorates EAE by Down Regulating Cell
Adhesion Molecules and Repressing IL-17 Production
Having established that CpdA - at least at certain concentra-
tions - ameliorates EAE, we wanted to identify the underlying
mechanisms. To this end, we induced EAE in C57Bl/6 wildtype
mice by immunization with MOG35–55 peptide followed by CpdA
therapy using both the intermediate and the low dose of CpdA
following the same protocol as in the previous experiments.
CpdA treatment reduced lymphocyte infiltration into the spinal cord
at 5 as well as 1.5 mg/kg, thus providing a reasonable explanation for
the improved clinical disease course after therapy. However, neither
the level of apoptosis nor the expression of cell adhesion molecules such
as LFA-1 and CD44 were altered in CNS-infiltrating T cells (Fig. 6A
and data not shown). This is in line with our previous observation that
Figure 3. CpdA-induced apoptosis is independent of the GR. (A,B) Thymocytes were isolated either from GRN
+/+ or GRN
2/2 E18.5 embryos
and cultured in the absence (con) or presence of different concentrations of Dex (A) or CpdA (B) for 24 hrs. Apoptosis was assessed by flow cytometry
based on AnnexinV/7-AAD staining. Survival of untreated cells was set as 100% for each time point to correct for spontaneous apoptosis. n=3. (C,D)
WEHI 7.1 cells stably transduced with a retrovirus encoding a GR-specific shRNA (GR-siRNA), Bcl-2 or the empty retroviral vector LMP, were cultured in
the absence (con) or presence of different Dex concentrations (C) or 10
25 M CpdA (D) for 24 hrs. Apoptosis was assessed by flow cytometry based
on AnnexinV/7-AAD staining. Survival of untreated cells was set as 100% for each time point to correct for spontaneous apoptosis. n=325.
*: p,0.05, **: p,0.01, n.s.: p.0.05.
doi:10.1371/journal.pone.0008202.g003
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peripheral immune system and only indirectly impact on CNS
infiltration [19]. Therefore, we subsequently studied effects of CpdA on
CD4
+ Th cells in the spleen. While the percentage of apoptotic cells
was again unaltered, surface expression levels of LFA-1 and CD44
w e r er e d u c e do nT hc e l l sf r o mC p d At r e a t e dm i c ei nad o s e - d e p e n d e n t
manner (Fig. 6B). In addition, we investigated the proliferative capacity
as a measure of T cell priming and the production of effector cytokines
after restimulation with ConA or the cognate antigen. There was no
difference in terms of proliferation and IFNc production between both
treatment groups irrespective of whether stimulation was achieved by
ConA or MOG35–55 peptide (Fig. 6C,D). In contrast, IL-17 levels in
cultures from CpdA treated mice were significantly reduced after
restimulation with MOG35–55, which was not the case after polyclonal
stimulation with ConA (Fig. 6D). This indicates that CpdA selectively
impacts antigen-specific Th17 cells known to play an essential role in
the pathogenesis of EAE [31–33], thereby corroborating the notion
that IL-17 but not IFNc is the central mediator of this disease [34].
Discussion
GCs are highly potent anti-inflammatory drugs that are used to
treat a variety of diseases such as RA, asthma or MS [2,3,35].
Nevertheless, systemic application is often accompanied by
Figure 4. Decay of CpdA into aziridine derivatives and synephrine depends on the solvent and pH. (A) Schematic depiction of the in
vitro decay of CpdA in pure water (upper part) and PBS (pH=7.6) or Tris-HCl (pH=7.6) buffer (lower part) based on
1H NMR spectroscopic analysis.
When dissolved in water, CpdA directly decomposes into acetyl synephrine within approximately 5 days, followed by ester hydrolysis into synephrine
after several weeks to months. In contrast, dissolving CpdA in buffered solutions leads to the formation of a mixture of the corresponding cis and
trans aziridines, which can be detected by
1H NMR spectroscopy within minutes. With a half-life (t1/2) of several days the aziridines then become
hydrolyzed into acetyl synephrine and subsequently synephrine. (B) The half-life of CpdA dissolved in phosphate-buffered solutions with pH values of
6.7, 7.1, 7.7 and 8.1 was determined by
1H NMR spectroscopy and its logarithm was plotted against the pH value. The exact values and the linear
regression curve are depicted in the graph. r
2 indicates the correlation coefficient.
doi:10.1371/journal.pone.0008202.g004
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[5]. Since it is believed that beneficial effects are often mediated by
GR transrepression while many side effects rely on GR
transactivation, current research aims at identifying novel
substances that dissociate these two features. A promising
candidate for such a drug is CpdA [12]. In this work we could
show that CpdA indeed represses inflammatory mediators in
myelin-specific T effector cells and fibroblasts in vitro in the absence
of gene activation. However, we found that CpdA added at the
same concentration also induces apoptosis in various cell-types
such as lymphocytes and neuronal cells. This activity of CpdA
proceeds via a Bcl-2- and caspase-dependent pathway and is fully
independent of the GR. A likely explanation for the dichotomy
observed in cell culture comes from our
1H NMR results. Despite
acting in principle as a dissociating GR-ligand, CpdA dissolved in
buffered solutions rapidly decomposes into aziridine derivatives
that are generally known as alkylating agents with strong pro-
apoptotic and neurotoxic potential [29,30].
Benzyl halides with a b-amino group such as CpdA are known
to form cyclic intermediates, which require the amino form while
the protonated ammonium form is not reactive [36]. Consequent-
ly, CpdA dissolved in water is relatively stable while it rapidly
decays in buffered solution with increasing pH. This brings along
several biological consequences. CpdA dissolved in standard
buffers such as PBS or Tris-HCl almost immediately decomposes
into its aziridine derivatives and thereby induces widespread GR-
independent apoptosis. Since this cannot be avoided in cell
culture, massive apoptosis takes place after prolonged incubation.
When CpdA is dissolved in water where it is chemically stable and
subsequently administered to animals, it also decomposes into the
toxic aziridines at the physiological pH of 7.4 unless quantitatively
stabilized by binding to proteins such as CBG [12]. We therefore
postulate that CpdA applied to mice at high concentrations results
in the formation of significant amounts of the aziridine derivatives,
which would explain why the mice die after injection of 15 mg/kg
CpdA or have to be sacrificed for ethical reasons. Nevertheless,
administration of 5 mg/kg as well as 1.5 mg/kg CpdA ameliorates
EAE in a GR-dependent manner. From this we conclude that
CpdA indeed possesses anti-inflammatory activity in vivo except
that the aziridine derivatives that are presumably formed in
animals at increased amounts additionally cause side effects
independent of the GR. This notion is in line with our observation
that low to intermediate doses of CpdA have little impact on
splenic cellularity while high-dose CpdA strongly decreases
leukocyte counts. We hypothesize that this toxic effect, which
possibly affects also many other cell types, is responsible for
the lethality observed after administration of CpdA at high
concentrations.
Despite the undeniable caveats related to the in vivo application
of CpdA, we could nevertheless confirm that it has significant
therapeutic potential in the treatment of EAE if applied at a
dosage of 1.5 to 5 mg/kg. Our mechanistic studies revealed that
CpdA acts by down regulating expression of the cell adhesion
molecules LFA-1 and CD44 on peripheral Th cells and by
repressing IL-17 production by antigen-specific effector T cells. In
contrast, CpdA neither has an affect on T cell priming nor on
IFNc production. This is in line with the previously proposed
model that Th17 rather than Th1 cells are central to the
development and pathogenesis of EAE [31,32] as well as MS [37].
Moreover, CpdA does not induce apoptosis in a GR-dependent
manner if applied at a low to intermediate dose. This corroborates
the model that CpdA indeed acts as a dissociating GR-ligand in
vivo in the treatment of EAE. In particular lymphocyte death, a
bona fide example of GR transactivation, is not induced at these
Figure 5. Treatment of MOG35–55 induced EAE by CpdA. (A) EAE
was induced in C57Bl/6 mice followed by treatment with 15 mg/kg
CpdA (dissolved in 20% ethanol), 100 mg/kg Dex or PBS as a control
(con) on 3 consecutive days starting at an average clinical score of 2
(marked by arrows); n=11; statistical analysis: days 11–22. The cross
indicates that all animals of this group either died or had to be
sacrificed for ethical reasons. The experiment was repeated twice with
similar results. (B) CpdA was dissolved in water and therapeutically
applied at doses of 5 mg/kg or 1.5 mg/kg for 3 consecutive days after
the mice had developed an average clinical score of 3 (marked by
arrows); treatment with the solvent alone (con) served as a control;
n=18/6/19; statistical analysis: days 13–23. The experiment was
repeated five times with similar results. (C) EAE was induced in C57Bl/
6 and GR
lckCre mice followed by treatment with CpdA dissolved in water
at a dose of 5 mg/kg or the solvent alone (con). Therapy was started at
an average score of 2 (defined as day 0); n=6; statistical analysis: days
1–10. The experiment was repeated twice with similar results. (D) C57Bl/
6 wildtype or GR
lckCre mice were treated with 5 mg/kg or 15 mg/kg
CpdA dissolved in water or PBS as a control on 3 consecutive days. On
the following morning surviving mice were sacrificed and the cellularity
of the spleen was determined by microscopic counting. n=3/12.
**: p,0.01, ***: p,0.001, n.s.: p.0.05.
doi:10.1371/journal.pone.0008202.g005
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efficiently occurs. It is noteworthy that these data are the first piece
of evidence indicating that transactivation and apoptosis induction
might be dispensable for the anti-inflammatory activity of GCs in
the treatment of EAE and MS.
Taken together, we have confirmed the dissociating nature of
CpdA in vitro and in vivo and established its therapeutic efficacy in
EAE as a model of human MS if administered at certain dosages.
However, we also found that it exerts GR-independent vulnerable
side effects at high concentrations by inducing apoptosis in vitro and
diminishing cell numbers in vivo, eventually leading to the death of
all treated mice. Undeniable, this severely hampers the in vivo use
of CpdA in humans due to the narrow therapeutic window
available for the treatment of inflammatory diseases and due to the
potential dramatic adverse effects that occur if CpdA is only
marginally misdosed.
Figure 6. Mechanism of CpdA action in the treatment of EAE. (A) EAE was induced in C57Bl/6 mice followed by treatment with 1.5 mg/kg or
5 mg/kg CpdA dissolved in water for 3 consecutive days after the mice had developed an average clinical score of 3. On the following morning the
mice were sacrificed and the leukocytes isolated from the spinal cord. Cellularity was determined by microscopic counting; staining for AnnexinV
binding and surface expression of LFA-1 on CD3
+CD4
+ Th cells was performed by flow cytometry. n=327. (B) The spleen was isolated from the same
animals as in panel A and the leukocytes analyzed for AnnexinV binding as well as LFA-1 and CD44 surface expression on CD3
+CD4
+ Th cells by flow
cytometry. n=328. (C, D) Splenocytes from the same animals as in panels A and B were cultured in the presence or absence of ConA or MOG35–55
peptide. Proliferation was measured by
3[H]-thymidine incorporation assay and expressed as a proliferation index relative to the values obtained
in the absence of any stimulus (C); IL-17 and IFNc levels in the supernatant were determined by ELISA (D); n=7210. *: p,0.05, ***: p,0.001,
n.s.: p.0.05.
doi:10.1371/journal.pone.0008202.g006
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